- $5.75bn
- $7.13bn
- $2.66bn
- 85
- 41
- 86
- 81
Annual income statement for Stericycle, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,309 | 2,676 | 2,647 | 2,705 | 2,659 |
Cost of Revenue | |||||
Gross Profit | 1,190 | 1,060 | 1,017 | 1,026 | 1,015 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3,544 | 2,644 | 2,575 | 2,551 | 2,582 |
Operating Profit | -235 | 31.9 | 72.3 | 154 | 77.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -363 | -56 | 0.7 | 78.9 | 3.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -346 | -100 | -28.7 | 56.5 | -21.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -347 | -57.3 | -27.8 | 56 | -21.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -347 | -57.3 | -27.8 | 56 | -21.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.225 | 0.471 | 0.825 | 0.963 | 1.1 |